ABBV-0805 is under clinical development by BioArctic and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ABBV-0805’s likelihood of approval (LoA) and phase transition for Parkinson’s Disease took place on 21 Apr 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ABBV-0805 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ABBV-0805 overview

ABBV-0805 (BAN-0805) is under development for the treatment of Parkinson's disease. The drug candidate is a monoclonal antibody which acts by targeting aggregated/misfolded protein called alpha-synuclein. It is developed based on antibody technology. It was also under development for the treatment of dementia with Lewy bodies. It is administered through intravenous route.

BioArctic overview

BioArctic, formerly BioArctic Neuroscience, is a biopharma company that develops new immunotherapeutic treatments for patients with central nervous system disorders. The company develops drugs for neurological disorders such as Parkinson’s disease, Alzheimer’s disease, and spinal cord injury. It develops alzeimer antibodies. BioArctic’s reagents include AB antibody AbetaN, Alzheimer biomarker and parkinson biomarker. The company’s antibodies have the capability to reduce soluble, toxic aggregated proteins in the brain. It develops new treatments for Parkinson’s disease and Dementia with Lewy bodies. The company collaborates with research groups at universities and hospitals. BioArctic is headquartered in Stockholm, Sweden.

Quick View ABBV-0805 LOA Data

Report Segments
  • Innovator
Drug Name
  • ABBV-0805
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.